Anacor Issues Update on Arbitration with Valeant, Says Prelim. Injunction Hearing Cancelled
May 02, 2013 at 18:02 PM EDT
Anacor Pharmaceuticals (NASDAQ: ANAC ) today announced that Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), or Valeant, has agreed that the launch of efinaconazole, its topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve our breach of contract dispute with Valeant. As